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Abstract: Placental cytokine balance may be critical for the control of mother-to-child transmission (MTCT) of HIV. We 
assessed whether the type and duration of antiretrovirals used for prevention of HIV-1-MTCT modified the inflammatory 
cytokine profile. We investigated the levels of cytokine expression in the placentas of 61 HIV-1-infected women who re-
ceived zidovudine (ZDV) plus single dose nevirapine (SD-NVP) or ZDV only for prevention of MTCT. Placentas of 38 
HIV-1-uninfected women were included as controls. All placentas were obtained after vaginal delivery. Levels of mRNA 
and cytokine expression were quantified using real-time PCR and ELISA, respectively, in placental explants and 24-hour 
culture supernatants and analyzed in relation to the women’s characteristics and the type and duration of antiretroviral 
prophylaxis. HIV-1-infected and uninfected women did not show any differences in the expression of placental cytokine 
secretion except for a trend toward lower TNF- mRNA levels in HIV-1-infected women. Within the HIV-1-infected 
group, women who were exposed to a long duration of ZDV (>72 days) or received SD-NVP less than 5h prior to deliv-
ery, more frequently expressed detectable levels of IL-10 in their placentas (32% versus 7% (p = 0.01) and 32% versus 
5% (p = 0.02), respectively). No infant was found to be HIV-1-infected. Our results showed a normalization of the placen-
tal cytokine balance in HIV-1-infected women receiving antiretroviral prophylaxis. Furthermore, the type and duration of 
antiretroviral prophylaxis have an impact on the placental anti-inflammatory IL-10 expression level, which may contribute 
to controlling HIV replication at the placental level, thus reducing MTCT of HIV-1. 
Keywords: HIV-1, placenta, antiretroviral prophylaxis, zidovudine and nevirapine, IL-10 cytokine, mother-to-child transmis-
sion. 
INTRODUCTION 
 The placenta constitutes a powerful natural barrier to 
HIV-1 transmission, presumably through its double layer of 
polarized cells, cytotrophoblasts and syncytiotrophoblasts. 
Indeed, primary cultures of purified human trophoblasts [1, 
2] and trophoblast cell lines [3, 4] display limited permis-
siveness for HIV-1 infection by cell-free viruses and re-
stricted HIV-1 replication. Cytokine balance in the placental 
environment is known to play an important role not only in 
the maintenance of pregnancy but also in favoring or inhibit-
ing in-utero infection. For example, elevated levels of pla-
cental tumor necrosis factor-alpha (TNF-) were associated 
with poor pregnancy outcome and higher risk of transmitting 
malaria to the infant [5-7]. HIV-1 can up-regulate placental 
interleukin (IL)-1, IL-6, and TNF- pro-inflammatory  
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cytokines in vitro [8, 9]. These pro-inflammatory cytokines 
have been shown to activate HIV-1 proviral expression in 
trophoblast cells [10-12]. 
 Antiretroviral prophylaxis during pregnancy and labor, and 
in neonates dramatically reduces perinatal HIV-1 transmis-
sion. In the PACTG 076/ANRS 024 trial, the use of zi-
dovudine (ZDV) prophylaxis in non-breastfeeding women 
during pregnancy and labor and in neonates lowered the risk 
of transmission by two-thirds [13]. A single dose of nevirapine 
(SD-NVP) given to women at the onset of labor and to infants 
48-72 hours after birth decreased the risk of transmission by 
almost half [14]. When SD-NVP was administered to women 
at the onset of labor in addition to ZDV prophylaxis starting 
from 28 weeks of gestation, mother-to-child HIV-1 transmis-
sion was reduced to less than 2% [15]. The effect of these 
antiretroviral drugs on decreasing maternal HIV viral load is 
insufficient to fully explain their efficacy for the reduction of 
perinatal HIV-1 transmission rates. For example, in the 
PACTG 076/ANRS 024 trial, the median viral load decrease 
associated with ZDV prophylaxis in HIV-1 infected pregnant 
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women was 0.3 log10 copies/ml [16]. In the HIVNET006 
study, a single dose of nevirapine given at the onset of labor 
resulted in a median viral load decrease of 1.3 log10 copies/ml 
at 1 week postpartum [17]. This suggests that there are addi-
tional mechanisms through which antiretrovirals prevent 
MTCT of HIV-1. Since both drugs easily cross the placenta, a 
pre- or post-exposure prophylactic effect in the neonate is very 
likely [15]. In addition, modification of the placental cytokine 
environment may contribute to reducing transmission. 
 Our objective was to determine whether the type and 
duration of antiretrovirals used for prevention of HIV-1 
MTCT can modify the placental cytokine balance. 
MATERIALS AND METHODS 
Study Population 
 This prospective study was conducted in 4 hospitals in 
Chiang Mai and Lamphun provinces in northern Thailand. 
The protocol was approved by the Ethics Committee of the 
Faculty of Associated Medical Sciences, Chiang Mai Uni-
versity. All women participating in this study provided writ-
ten informed consent. Women who had a vaginal delivery 
and did not give birth to twins were enrolled. HIV-1 infected 
women who delivered by caesarean section were excluded 
from the analysis. 
 Between April 2002 and September 2004, ninety-nine 
placentas, 61 from HIV-1 infected women and 38 from HIV-
1 uninfected women, were collected. Fifty-nine of the HIV-1 
infected women, enrolled at Health Promotion Center Re-
gion 10, Nakornping, and Lamphun hospitals, were partici-
pating in PHPT-2 [15] (ClinicalTrials.gov NCT00398684). 
They all received ZDV (300 mg twice daily) starting at 28 
weeks’ gestation, or as soon as possible thereafter. Accord-
ing to their randomization arm, women received either a 
single dose of NVP (200 mg) or a placebo at onset of labor. 
The remaining two HIV-1 infected women, enrolled at Ma-
haraj Nakorn Chiang Mai hospital, received ZDV starting at 
34 weeks’ gestation. 
 The following data were collected from all women: age, 
gestational age at delivery, and mode of delivery. For HIV-1 
infected women, the following additional data were col-
lected: antiretroviral prophylaxis (type, timing, and dura-
tion), CD4 cell count (cell/mm3) before 28 weeks of gesta-
tion and plasma HIV-1 RNA viral load at delivery (log10
copies/ml). 
 Diagnosis of HIV-1 infection in infants born to HIV-1 
infected mothers was performed using DNA PCR on dried 
blood spots (Amplicor® HIV-1 DNA assay version 1.5, 
Roche Molecular Systems Inc., Branchburg, NJ, USA) as 
previously described [15]. For infants born to women en-
rolled at the Maharaj Nakorn Chiang Mai hospital, HIV-1 
infection was assessed by HIV-1 serology (HIV Combi, 
Elecsys, Roche, Germany and Anti-HIV-1/2 Plus, En-
zygnost, Dade Behring, Germany) at 18 months of age. 
Placenta Processing 
 Within three hours post-delivery, placentas were proc-
essed to isolate placental chorionic villi as previously de-
scribed [18]. Fragments (< 0.5 cm of thickness) of placental 
chorionic villi were immersed in 1.5 mL of RNA stabiliza-
tion reagent (RNAlater™, Qiagen, Germany), stored imme-
diately at 2-8°C for 24 hours, and then transferred to -70°C. 
Six grams of placental chorionic villi were cultured for 24 
hours in 2 flasks (3 g/flask), each containing 20 mL of cul-
ture medium as previously described [18]. 
Quantification of Secreted Cytokines 
 Quantification of TNF-, IL-8, IL-10, IL-15, IL-16, and 
regulated on activation normal T-cell-expressed and secreted 
(RANTES) in the placental culture supernatants was per-
formed using a quantitative sandwich enzyme immunoassay 
(ELISA) technique with cytokine specific commercial kits as 
previously described [18]. Quantification of leukemia inhibi-
tory factor (LIF) was performed at the laboratory of Immu-
nology, CNRS UMR 5540, Université Bordeaux 2, France, 
using an in-house sandwich ELISA [19]. 
Quantification of Cytokine mRNA 
 Total RNA was extracted from thawed placental chorionic 
villi and reverse transcribed to cDNA using the Taqman
Reverse transcription kit (Applied Biosystems, Foster City, 
CA, USA). Stromal cell-derived factor (SDF)-1, TNF-, IL-8 
and IL-10 mRNA levels were quantified using the Taqman 
real-time PCR assay as previously described [18]. The cyto-
kine mRNA levels are expressed as multiples of the results 
obtained with reference cDNA, prepared from a term placental 
tissue of an HIV-1 uninfected woman, used as a calibrator (
cal). 
Statistical Analysis 
 Characteristics of the 2 groups, HIV-1 infected and unin-
fected women, are described by n (%) for qualitative data 
and median (inter-quartile range; IQR) for quantitative data. 
Results of cytokine secretion and mRNA expression levels 
are presented as median and IQR for each group. Compari-
son of cytokine secretion and mRNA expression median 
levels between groups was performed through the non-
parametric Mann-Whitney test. In addition, the proportion of 
women with detectable levels of cytokine secretion was 
compared between groups through the Chi-square test or the 
Fisher exact test, when necessary. Undetectable cytokine 
median levels were replaced by half of the value of the de-
tectability threshold. No comparison of cytokine median 
levels was performed if less than 50% of women in one 
group had a detectable level. 
 Cytokine secretion or mRNA expression levels were com-
pared in HIV-1 infected women according to the type, timing 
or duration of antiretroviral (ARV) prophylaxis. ZDV duration 
was divided into 2 categories according to the median, 72 
hours. The time interval between NVP intake and delivery was 
also categorized according to the rounded median, 5 hours. 
Furthermore, this 5-hour cut-off value is relevant in terms of 
pharmacokinetics since it has been shown that the peak NVP 
plasma concentration is reached 3 to 7 hours after single dose 
intake during labor [17, 20]. Comparisons were performed 
through the Mann-Whitney test for quantitative results (levels 
of secretion or mRNA expression) and through the Chi-square 
test or the Fisher exact test, when necessary, for qualitative 
results (proportion of women with detectable secretion levels). 
Comparisons yielding a p < 0.05 were considered significant. 
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RESULTS 
Characteristics of the Study Population 
 The demographic and gestational characteristics of the 
groups of HIV-1 infected and uninfected pregnant women 
are shown in Table 1. The median age at delivery was not 
significantly different between the 2 groups (26 versus 28 
years, p = 0.56), while the median gestational age at delivery 
was higher in the group of HIV-1 infected women (39.4 
versus 38.6 weeks, p = 0.05). The antiretroviral prophylaxis 
received and biological characteristics are shown for the 
group of HIV-1 infected women. Eighteen percent of HIV-1 
infected women received ZDV prophylaxis only. 
Infant HIV-1 Status 
 The HIV-1 status could be determined for 60 of the 61 
infants born to HIV-1 infected mothers - one was lost to 
follow up. Of the 60 infants with known HIV status, none 
were found to be HIV-1 infected. 
No Difference in the Expression Levels of Cytokine Se-
cretion Between HIV-1 Infected and Uninfected Women 
 Cytokines were quantified in placental culture super-
natants of HIV-1 infected women and expression levels were 
compared to those of uninfected women (Table 2). The pro-
portion of samples with detectable expression levels of IL-
10, TNF-, and LIF as well as the median expression levels 
of LIF, IL-8, IL-15, IL-16, and RANTES were not signifi-
cantly different between HIV-1 infected and uninfected 
women (Table 2). 
No Difference in the Expression Levels of Cytokine 
mRNA Between HIV-1 Infected and Uninfected Women 
 Expression levels of mRNA for the pro-inflammatory 
cytokines TNF- and IL-8, the anti-inflammatory cytokine 
IL-10, and the chemokine SDF-1 were quantified in placen-
tal explants of HIV-1 infected and uninfected women (Table 
3). A trend toward lower TNF- mRNA median expression 
levels was observed in placentas of HIV-1 infected women 
(p = 0.06) while the median expression levels of SDF-1, IL-
8, and IL-10 mRNA of HIV-1 infected women were not 
significantly different from those of HIV-1 uninfected 
women. 
Placenta Inflammatory Profile in Immunocompromised 
Women 
 Analysis of the relation between the maternal CD4 level 
and placental cytokine profile showed that women (n = 19) 
with CD4 count less than or equal to 250 cells/mm3 ex-
pressed higher placental TNF- mRNA (2.7 versus 1.1  cal, 
p = 0.007) and IL-8 secretion levels (2,013 versus 1,517 
pg/ml, p = 0.02) than women with CD4 count higher than 
250 cells/mm3 (n = 42). 
Long Duration of ZDV Prophylaxis is Associated with 
Higher Placental IL-10 Secretion Level 
 We then assessed among HIV-1 infected women the effect 
of the duration of ZDV prophylaxis on the level of cytokine 
expression. TNF-  and IL-10 secretions were analyzed since 
TNF- is a pro-inflammatory cytokine known to stimulate 
HIV-1 replication and IL-10 is an anti-inflammatory cytokine 
which inhibits the expression of TNF- mRNA. The median 
expression level of TNF-mRNA of women who had a long 
ZDV prophylaxis duration (> 72 days) was not significantly 
different from that of women who had a ZDV prophylaxis 
duration less than or equal to 72 days (1.8 versus 1.7  cal, p = 
0.30). In contrast, the proportion of supernatants with detect-
able levels of IL-10 was significantly higher in women who 
received ZDV prophylaxis for more than 72 days than in those 
who had a ZDV prophylaxis duration less than or equal to 72 
days (32% versus 7%, p = 0.01) (Fig. 1). 
Table 1. Characteristics of the Study Population 
Enrolment Sites HIV-1 Infected Women (n = 61) HIV-1 Uninfected women (n = 38) 
Maharaj Nakorn Chiang Mai Hospital 











Characteristics:   
Age at delivery (years) 26 (22-31) 28 (23-30)  
Gestational age at delivery (weeks) 39.4 (37.9–40.4) 38.6 (38.0-39.0)  
Gestational age at ZDV prophylaxis initiation (weeks) 29 (28-39) Not Relevant 
Duration of ZDV prophylaxis (days) 72 (54–81) Not Relevant 
NVP plus ZDV prophylaxis 50 (82%) Not Relevant 
Time to delivery after NVP dosing (hours) 4.4 (1.9-8.2) (n = 46) Not Relevant 
CD4 cell count before 28 weeks gestation (cells/mm3) 332 (241–494) Not Relevant 
HIV RNA load at delivery (log10 copies/ml) 4.1 (3.3–4.6) (n = 57) Not Relevant 
The data are expressed as median (interquartile range) or n. 
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Administration of NVP Less Than 5 Hours Prior to De-
livery is Associated with Higher Placental IL-10 Secre-
tion Level 
 The median expression level of TNF- mRNA in women 
who received ZDV plus NVP was comparable to that of 
women who received ZDV only (1.6 versus 2.3  cal, p = 
0.24). Among women who received a single dose of NVP 
during labor, TNF- mRNA expression levels were similar 
in those who received NVP at least 5 hours prior to delivery 
and those who received NVP less than 5 hours prior to deliv-
ery (1.1 versus 1.6  cal, p = 0.19). Similarly, the proportion 
of placentas with detectable expression levels of IL-10 was 
not different between women who received ZDV plus NVP 
and those who received ZDV only (18% versus 27%, p = 
0.48) (Fig. 2A). However, among women who received a 
single dose of NVP during labor, detectable IL-10 secretion 
levels were found in higher proportion of those who received 
NVP less than 5 hours prior to delivery than in those who 
received NVP later (32% versus,5%, p = 0.02) (Fig. 2B). 
DISCUSSION 
 We report here, for the first time, an association between 
a higher expression level of the anti-inflammatory IL-10 
cytokine in the placenta and either a longer ZDV prophylaxis 
duration or a shorter time to delivery after intake of NVP 
during labor. 
Fig. (1). Proportion of detectable IL-10 levels ( 5 pg/ml) in pla-
cental culture supernatants of HIV-1 infected women according to 
ZDV prophylaxis duration (72 days). IL-10 was evaluated by 
ELISA. 
 HIV-1 infected patients usually exhibit high levels of 
inflammatory cytokines. The fact that no significant differ-
ences were observed between the median placental cytokine 
levels of HIV-1 infected and uninfected women suggests a 
possible effect of ARV in regulating cytokine expression at 
the placental level. However, this hypothesis could not be 
ascertained since all HIV-1 infected women in the study 
received ZDV or ZDV plus NVP. In the present study, pla-
centas of HIV-1 infected women showed a trend toward 
lower median expression of TNF- mRNA than placentas  
Table 2. Cytokine Secretion Levels in Supernatants of 24h-Culture of Placental Explants from HIV-1 Infected and Uninfected 
Pregnant Women 
Secretion of Cytokines and Chemokines HIV-1 Infected Women (n = 61) HIV-1 Uninfected Women (n = 38) p
IL-10 detectable samples (%) 20 18 0.88b
TNF- detectable samples (%) 48 32 0.12b








IL-8 (pg/ml)a 1787 (1086-2271) 1840 (1086-2702) 0.81c
IL-15 (pg/ml)a 11.0 (8.2-16.1) 10.8 (6.9-15.7) 0.48c
IL-16 (pg/ml)a 404 (253-585) 424 (249-512) 0.83c
RANTES (pg/ml)a 506 (296-726) 477 (359-795) 0.86c
The data are expressed as percentage of detectable samples and/or median (interquartile range). 
a All samples had detectable level of cytokines. 
b Chi-square test. 
c Mann-Whitney test. 
Table 3. Placental Cytokine mRNA Levels 
Expression of Cytokine and Chemokine mRNA (  cal) HIV-1 Infected women (n = 61) HIV-1 Uninfected Women (n = 38) pa
SDF-1 2.8 (1.6-6.7) 3.2 (1.9-6.4) 0.95 
TNF- 1.8 (0.8-4.9) 2.8 (1.7-4.5) 0.06 
IL-8 2.4 (0.6-6.1) 3.1 (1.0-7.4) 0.37 
IL-10 2.5 (1.2-6.2) 3.2 (1.8-5.3) 0.36 
The data are expressed as median (interquartile range). The cytokine mRNA levels are expressed as multiples of the results obtained with a reference cDNA prepared from a term 
placental tissue of a HIV-1 uninfected woman and used as a calibrator ( cal). 
a Mann-Whitney test. 
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of HIV-1 uninfected women (Table 3), suggesting that ZDV 
or ZDV plus NVP might decrease the expression of TNF-
mRNA. This hypothesis is consistent with our previous in 
vitro study showing a decrease of TNF- transcripts when 
ZDV was added to normal placental histoculture [21]. Thus, 
ZDV or the combination of ZDV plus NVP may contribute 
to the normalization of the placental cytokine balance in 
HIV-1 infected women. This is also consistent with the Hy-
gino et al. report [22] showing similar lymphoproliferation 
and IL-4, IL-10, IFN- and TNF- levels in cord blood of 
neonates born to HIV-1 infected mothers who controlled 
their plasma HIV RNA and neonates born to HIV-1 unin-
fected mothers. Moreover, neonates born to HIV-1 infected 
mothers who received ZDV plus NVP during pregnancy had 
significantly higher IL-10 levels in their plasma than those 
born to untreated HIV-1 infected mothers. 
 In our study, a long ZDV prophylaxis duration (> 72 
days) was associated with a higher proportion of detectable 
IL-10 secretion levels (p = 0.01). This proportion was also 
higher when NVP was given less than 5 hours prior to deliv-
ery (p = 0.02). These data suggest that ZDV itself could 
increase the production of IL-10 and this effect might be 
synergized by NVP. The effect of NVP on IL-10 secretion, 
which cannot be observed more than 5 hours after admini-
stration, is more difficult to interpret and could be related to 
a short duration of labor. Another possible explanation is that 
initial induction of IL-10 secretion during the first 5 hours 
after NVP intake could be followed by inactivation of IL-10 
secretion through a negative feedback mechanism as a result 
of prolonged exposure to NVP [23-25]. However, this “aner-
gic” state was not described by Schramm et al., who reported 
an increase in plasma activation markers such as neopterin, 
2-microblobulin, and soluble L-selectin in women exposed 
to SD-NVP [22]. Another hypothesis could be that the se-
creted IL-10 binds to its receptors and can no longer be de-
tected in our system 5 hours after NVP intake. A recent pa-
per also highlighted the impact of the duration of ARV 
treatment on the risk of HIV-1 MTCT in women with a low 
viral load and vaginal delivery [26]. 
 Although an alteration of the TNF-/IL-10 balance to-
ward a pro-inflammatory cytokine profile has been associ-
ated with HIV-1 disease progression [27, 28], whether or not 
the increase of anti-inflammatory IL-10 cytokine, resulting 
from ZDV or ZDV plus NVP, may participate in the control 
of HIV-1 replication is still unclear. The fact that immuno-
compromised women expressed higher placental TNF-
mRNA and IL-8 secretion levels likely reflects their more 
advanced disease stage. The sample size was too limited to 
analyze these results according to the type and duration of 
the ARV prophylaxis. In comparing placental cytokine pro-
files from transmitting versus non-transmitting mothers, 
Behbahani et al. reported an imbalance of placental cytokine 
Fig. (2). Proportion of detectable IL-10 levels ( 5 pg/ml) in placental culture supernatants of HIV-1 infected women according to the ARV 
prophylaxis regimen. (A) Women received ZDV only or ZDV plus a single dose of NVP at onset of labor. (B) Women received NVP less 
than 5 hours or at least 5 hours prior to delivery. IL-10 was evaluated by ELISA. Time from NVP intake to delivery was not available for 4 
HIV-1 infected women.
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distribution towards lower levels of IL-2 and higher levels of 
IL-4 and IL-10 cytokines in the placenta of HIV-1 non 
transmitting mothers [29]. In the present study, it was not 
possible to assess whether or not placental cytokine levels 
were associated with perinatal HIV-1 transmission since no 
infant was infected by HIV-1. 
 The exact molecular mechanisms by which ZDV and 
NVP control HIV-1 transmission through placental cytokine 
balance are not known. A possible mechanism could be that 
ZDV and NVP exert their activity through the transcriptional 
NF-kB pathway to down-regulate TNF- gene expression, 
thus diminishing HIV replication [30]. 
 In conclusion, this study demonstrates that longer zi-
dovudine prophylaxis and shorter time to delivery after NVP 
dosing are associated with a higher placental anti-
inflammatory IL-10 expression. This effect may contribute 
to reducing MTCT of HIV-1 through a reduction in HIV 
replication at the placental level. Therefore, the effect of 
ARV drugs on placental cytokine profiles should be consid-
ered in developing further strategies to prevent HIV-1 
MTCT. 
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